The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Molecular Subtypes and Radiotherapy as Determinants of Survival in Invasive Breast Cancer: Insights from a Single-Center Study

Authors: Qian Liu, , Fan Hu, , Yong Liu, , Chubo Qi, , Fanrong Liu,

Abstract

Objectives: Invasive breast cancer (IBC) is a heterogeneous disease, with molecular subtypes guiding treatment and prognosis. Radiotherapy, a key component of breast cancer therapy, may vary in efficacy across subtypes. This study assessed the distribution of molecular subtypes and the use of radiotherapy, as well as their associations with clinicopathological features, overall survival (OS), and disease-free survival (DFS) in a single-center cohort.

Methods: We retrospectively analyzed 178 IBC patients diagnosed between 2018 and 2021. Associations between molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 enriched, triple-negative breast cancer [TNBC]) and clinical features were assessed via χ2 tests. Kaplan-Meier and Cox regression analyses were performed on 158 patients with follow-up, after propensity score matching.

Results: Tumor size (P = 0.012), American Joint Committee on Cancer stage (P = 0.004), histological grade (P < 0.001), and chemotherapy (P = 0.016) differed significantly among the four molecular subtypes. OS and DFS varied by subtype (P = 0.024 and P = 0.042), with TNBC showing poorer outcomes than luminal B (OS P = 0.006, DFS P = 0.007) and luminal A (OS P = 0.035). Radiotherapy was associated with improved OS and DFS (P = 0.04 and P = 0.03). Multivariate Cox analysis confirmed radiotherapy as an independent factor for improved OS (hazard ratio 0.112; 95% confidence interval 0.022–0.566) and DFS (hazard ratio 0.129; 95% confidence interval 0.026–0.632).

Conclusions: IBC displays molecular subtype-specific differences in tumor behavior and prognosis, with TNBC linked to the worst clinical outcomes. Radiotherapy independently improved OS and DFS across all subtypes, supporting its continued role regardless of molecular profile.
Posted in: Breast Cancer21

Full Article

Having trouble viewing the article content below? Click here to open it directly.

Images

Download Image

Download Image

Download Image

References

1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73: 17–48.
 
2. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–752.
 
3. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019;321:288–300.
 
4. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736–750.
 
5. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492–2502.
 
6. Leeha M, Kanokwiroon K, Laohawiriyakamol S, et al. Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance. Pathol Oncol Res 2023;29:1611162.
 
7. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006;8:R34.
 
8. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.
 
9. Shan R, Dai LJ, Shao ZM, et al. Evolving molecular subtyping of breast cancer advances precision treatment. Cancer Biol Med 2024;21:731–739.
 
10. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373:307–316.
 
11. Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015;373:317–327.
 
12. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019;20:352–360.
 
13. Lu Y, Meng D, Hui B, et al. The deep inspiration breath-hold technique may be a win-win option for the treatment of patients in node-positive early left-sided breast cancer. J Clin Oncol 2022;40:3668–3669.
 
14. Holt F, Probert J, Darby SC, et al. Proton beam therapy for early breast cancer: a systematic review and meta-analysis of clinical outcomes. Int J Radiat Oncol Biol Phys 2023;117: 869–882.
 
15. Meattini I, Becherini C, Caini S, et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol 2024; 25:e73–e83.